OGT and Applied InSilico Announce Development Agreement
News Nov 21, 2005
Oxford Gene Technology (OGT) and Applied InSilico (AI) have announced a development agreement whereby AI will provide computational analysis services to OGT.
AI will use its ELE™ (Evolutionary Learning Environment) software platform to analyse data generated from OGT's microarray technology and services.
In addition, as part of the agreement, the two companies will collaborate on a series of projects designed to deliver a range of new products and services for life science research.
James Clough, OGT's Commercial Director, said, "AI provides innovative solutions to analyse complex data sets which, combined with OGT's extensive knowledge of microarrays and their applications, provide a powerful combination to address the challenges of unravelling genetic complexity."
Commenting on the announcement, Clive Briant, AI's VP, Business Development, said, "This agreement really formalises an already excellent relationship between AI and OGT."
"We have worked closely together on several leading edge research projects and it is clear that OGT and AI have complementary technologies and similar goals to deploy their innovative solutions within the life science industry."
"For example, we are both interested in the possibilities surrounding predictive diagnostics and creating intelligent medical devices."
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.